Soluble ACE2 as a Risk or Prognostic Factor in COVID-19 Patients: A Cross-sectional Study

  1. Parsa Mohammadi
  2. Hesam Aldin Varpaei
  3. Arash Seifi
  4. Sepideh Zahak Miandoab
  5. Saba Beiranvand
  6. Sahar Mobaraki
  7. Mostafa Mohammadi
  8. Alireza Abdollahi

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.47176/mjiri.36.135
  2. ScreenIT

    SciScore for 10.1101/2021.05.02.21256329: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: The study also has been approved in ethics committee of Tehran University of medical sciences with ethic code: 99/11/101/16529.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    No key resources detected.

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    It could be because there was no correlation or due to limitation of our sample size. In the present study, we did not find a significant difference in the serum ACE2 levels of the two groups of patients, which is aligned with similar studies [17,18]. However, we find that serum ACE 2 level was rise in patients with severe disease, who finally expired. Some studies hypothesized that, A significant increase of serum ACE2 activity may act as an endogenous nonspecific protective mechanism against SARS-CoV-2 infection that preceded the recovery of patients [19]. A study by Emilsson et al [20], suggested that upregulation of ACE2 levels may reflects severity of outcome in COVID-19. Besides, it seems that serum ACE activity on admission did not reflect disease severity [18]. Further studies are required for confirmation of association between serum ACE 2 and COVID-19 severity. It was suggested that, Measurement of serum ACE2 antibody titers would help to identify who is likely to progress into acute respiratory distress, particularly in patients with cardiovascular disease and hypertension [21], Therefore, it might be possible to use serum ACE2 as indicator of ARDS.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.05.02.21256329v1 on medRxiv